Our publ in Lancet: IPD pooled analysis of all 6 RCTs in which 23,256 pts were treated with 1-yr DAPT vs. 2wks-3mos DAPT (median 78d) followed by ticagrelor monoRx. MACE favored short DAPT, and major bleeding and mortality were reduced. Similar results in CCS & ACS, even post-MI.
Thrombin (blood clotting) is elevated after a heart attack & is associated with worse outcomes. Inhibiting thrombin improved death, heart attack & stroke in 4 previous trials.
We are testing the hypothesis with factor xi inhibition to reduce bleeding in 16,000 pts at 1000 sites❤️
Novel molecules that can ultimately be produced at low cost will transform CV risk. The LeBauer-Brodie Center will help drive the revolution
#Ionis#ACC#ConeHealth#Lipids
Dr Kardie Tobb discussing cardiovascular health equity at NCSC American College of Cardiology Annual Scientific Session at the Grove Park
#ACC#NCCACC#ConeHealth#healthequity #
Join us November 10 @TangerCenter for SHARE THE BEAT, the annual benefit in support of the Heart and Vascular Patient Care Fund. Fifty returns for a great evening of fun and entertainment.
NEWS: An update on the outcome of today’s FDA panel meeting on the Paradise Ultrasound Renal Denervation System PMA, our investigational device in the U.S. for treatment of hypertension: https://t.co/euBCo64Fqh
#RenalDenervation#Hypertension#uRDN
In the U.S., two-thirds of patients with T2D will develop ASCVD. The DCRI-led COORDINATE-Diabetes trial shows how a multidisciplinary approach to treatment can “increase the prescriptions of the therapies proven effective for patients,” says @NPagidipati: https://t.co/7iNdwul3l0